Literature DB >> 31054895

Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.

Priyanka D Sehgal1, Tyler M Bauman2, Tristan M Nicholson3, Jordan E Vellky4, Emily A Ricke5, Weiping Tang6, Wei Xu7, Wei Huang8, William A Ricke9.   

Abstract

Androgens and estrogens, working together, promote prostate cancer (PRCA) initiation and progression, with androgens acting via androgen receptor (AR) and estrogens acting primarily through estrogen receptor α (ERα). While the interplay between these steroid hormones has been established, the interaction between steroid hormone receptors in prostatic disease remains unstudied. The goal of this study was to objectively determine the incidence, stage specificity, and tissue/cell type specificity of AR and ERα expression, both independently and simultaneously, during the progression of PRCA. Using multiplexed immunohistochemistry and multispectral imaging analysis, AR, ERα, and smooth muscle α-actin expression was detected and quantitated in benign prostate tissue (BPT), high-grade prostatic intraepithelial neoplasia (HGPIN), PRCA, and metastasis (MET) from patient specimens (n=340). Epithelial AR expression was significantly increased in HGPIN, PRCA, and MET compared with BPT, whereas ERα expression in epithelial and stromal cells was highest in HGPIN. With analysis of AR and ERα coexpression, we identified a unique population of double-positive (AR+/ERα+) cells that increased in HGPIN specimens in both the stroma and the epithelium. Double-negative (AR-/ERα-) cells significantly decreased across PRCA progression, from 65% in BPT to 30% in MET. Preliminary analysis of this AR+/ERα+ population indicates potential cell type specificity in smooth muscle α-actin-negative stromal cells. This study demonstrates stage-, tissue-, and cell type-specific AR and ERα expression changes during PRCA progression, both independently and coexpressed. A more complete understanding of steroid hormones and their receptors in the initiation and progression of prostatic disease may elucidate improved strategies for PRCA prevention or therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgens; Epithelium; Estrogens; Prostate cancer; Stroma

Mesh:

Substances:

Year:  2019        PMID: 31054895      PMCID: PMC6642018          DOI: 10.1016/j.humpath.2019.04.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

1.  Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue.

Authors:  J Brolin; L Skoog; P Ekman
Journal:  Prostate       Date:  1992       Impact factor: 4.104

2.  Selective estrogen receptor modulators for the chemoprevention of prostate cancer.

Authors:  M S Steiner; S Raghow; B L Neubauer
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

Review 3.  Role of estrogens in development of prostate cancer.

Authors:  Pirkko L Härkönen; Sari I Mäkelä
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-19       Impact factor: 4.292

4.  Steroid hormones stimulate human prostate cancer progression and metastasis.

Authors:  William A Ricke; Kenichiro Ishii; Emily A Ricke; Jeff Simko; Yuzhuo Wang; Simon W Hayward; Gerald R Cunha
Journal:  Int J Cancer       Date:  2006-05-01       Impact factor: 7.396

Review 5.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

6.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 7.  Androgen receptor in prostate cancer.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

8.  Imaging analysis of subcellular correlation of androgen receptor and estrogen receptor alpha in single living cells using green fluorescent protein color variants.

Authors:  Ikuo Ochiai; Ken-Ichi Matsuda; Mayumi Nishi; Hitoshi Ozawa; Mitsuhiro Kawata
Journal:  Mol Endocrinol       Date:  2003-10-16

9.  Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate.

Authors:  G W Chodak; D M Kranc; L A Puy; H Takeda; K Johnson; C Chang
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.

Authors:  Rile Li; Thomas Wheeler; Hong Dai; Anna Frolov; Timothy Thompson; Gustavo Ayala
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

View more
  9 in total

1.  Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.

Authors:  Jordan E Vellky; Tyler M Bauman; Emily A Ricke; Wei Huang; William A Ricke
Journal:  Prostate       Date:  2019-09-10       Impact factor: 4.104

2.  Estrogen Receptors Promote Migration, Invasion and Colony Formation of the Androgen-Independent Prostate Cancer Cells PC-3 Through β-Catenin Pathway.

Authors:  Ana Paola G Lombardi; Carolina M Vicente; Catarina S Porto
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

3.  Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

Authors:  Zongwei Wang; Tuo Deng; Xingbo Long; Xueming Lin; Shulin Wu; Hongbo Wang; Rongbin Ge; Zhenwei Zhang; Chin-Lee Wu; Mary-Ellen Taplin; Aria F Olumi
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

4.  Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3.

Authors:  Ana Paola G Lombardi; Renan P Cavalheiro; Catarina S Porto; Carolina M Vicente
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 5.  Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention.

Authors:  Zeeshan Javed; Khushbukhat Khan; Amna Rasheed; Haleema Sadia; Muhammad Naeem Shahwani; Asma Irshad; Shahid Raza; Bahare Salehi; Javad Sharifi-Rad; Hafiz A R Suleria; Natália Cruz-Martins; Cristina Quispe
Journal:  Cancer Cell Int       Date:  2021-01-26       Impact factor: 5.722

Review 6.  Understanding and targeting prostate cancer cell heterogeneity and plasticity.

Authors:  Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-11-26       Impact factor: 17.012

Review 7.  Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.

Authors:  Wout Devlies; Markus Eckstein; Alessia Cimadamore; Gaëtan Devos; Lisa Moris; Thomas Van den Broeck; Rodolfo Montironi; Steven Joniau; Frank Claessens; Thomas Gevaert
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600

Review 8.  Development and prevalence of castration-resistant prostate cancer subtypes.

Authors:  Jordan E Vellky; William A Ricke
Journal:  Neoplasia       Date:  2020-09-25       Impact factor: 5.715

9.  RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.

Authors:  Jordan E Vellky; Sean T McSweeney; Emily A Ricke; William A Ricke
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-26       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.